Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 12/20 | 0.57 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070734 | 0.90 | GSK3B (0.47) | MPLPARP1MAPK10MAPK8DYRK1A | |
| SCHEMBL6070994 | 0.87 | KIF11 (0.50) | MPLPARP1MAPK10CSNK2A1DYRK1A | |
| SCHEMBL6071199 | 0.84 | AURKA (0.53) | MPLPARP1MAPK10MAPK8DYRK1A | |
| SCHEMBL6071492 | 0.82 | KDM4E (0.51) | MPLMAPK10RIPK1 | |
| SCHEMBL6071412 | 0.80 | MAPK10 (0.46) | MPLMAPK10DYRK1ARIPK1 | |
| SCHEMBL6070737 | 0.80 | KDM4E (0.46) | MPLMAPK10DYRK1ARIPK1 | |
| SCHEMBL6071274 | 0.80 | MAPK10 (0.41) | MAPK10DYRK1AGSK3AGSK3BCDK5 | |
| SCHEMBL6071032 | 0.80 | MAPK10 (0.59) | PARP1MAPK10MAPK8MAPK9DYRK1A | |
| SCHEMBL6070802 | 0.78 | MEN1 (0.49) | PARP1MAPK10MAPK8DYRK1AGSK3B | |
| SCHEMBL6071082 | 0.78 | MPL (0.54) | MPLPARP1MAPK10MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | claimed |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K1, MAP3K19, MAP3K20 | MPL 1056/4885PARP1 840/4885MAPK10 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.